http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2430233-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_358bb3af59dbb9335bab499271e3aed2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-08 |
| filingDate | 2001-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17fd669aef6968235c0c20cf02c8616a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51d30919dc2ac4d747dd2ad888a93a16 |
| publicationDate | 2002-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2430233-A1 |
| titleOfInvention | Synthesis and separation of optically active isomers of erythromycin and their biological actions |
| abstract | The present invention provides methods for purifying and using optically active isomers of erythromycin as well as compositions comprising such optically active isomers. Such optically active isomers having desired actions as an antibiotic substantially separable from undesirable effects on GI motility and the cardiac potassium channels such that the cardiac action potential is not prolonged and the QT interval on the surface EKG (electrocardiogram) is not increased, such that the erythromycin can be useful for more effective therapy of systemic infections. Also disclosed are methods for assaying the levels of such isomers present in the biological fluids. |
| priorityDate | 2000-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 140.